Rahul Ballal, PhD

Rahul is an Entrepreneur-in-Residence (EIR) and serves as Chief Business Officer of Northern Biologics, a Versant-backed immune oncology & fibrosis start-up. Prior to Versant and Northern, Rahul was VP of Business Development at Flexion Therapeutics (FLXN) where he led the company through several key transactions, including a $125M strategic manufacturing partnership with Patheon UK. Prior to Flexion, he ran business development at the Broad Institute where he completed several out-licensing deals, including the one that founded Verastem (VSTM). Rahul started his career in Silicon Valley as the founder/CEO of Redmind, a venture-backed data analytics start-up that he sold to Ikimbo Inc. in 2002. Rahul has a Ph.D. in cancer biology from Georgetown School of Medicine, an MS in bioinformatics from Johns Hopkins, and a BA from Brown University. He also completed his Kauffman Fellowship (Class 15) at Novartis Venture Funds.